SCHEMBL2884471

SCHEMBL2884471

CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](c2nc3nc(-c4ccccc4F)ccc3[nH]2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.35
ALOX5AP P20292 6/20 0.35
FEN1 P39748 6/20 0.35
MAP4K1 Q92918 1/20 0.34
ADORA3 P0DMS8 2/20 0.33
ADORA2B P29275 2/20 0.33
ADORA1 P30542 2/20 0.33
KCNH2 Q12809 1/20 0.33
NPY5R Q15761 2/20 0.33
HPGDS O60760 1/20 0.33
ADORA2A P29274 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
DGAT2 Q96PD7 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
BRAF P15056 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884473 1.00 USP30 (0.35) USP30ALOX5APFEN1MAP4K1ADORA3
SCHEMBL2879019 0.85 NPY5R (0.36) ALOX5APFEN1NPY5RALDH1A1POLB
SCHEMBL2881783 0.85 NPY5R (0.36) ALOX5APFEN1NPY5RALDH1A1POLB
SCHEMBL2879017 0.85 NPY5R (0.36) ALOX5APFEN1NPY5RALDH1A1POLB
SCHEMBL90943 0.82 CNR1 (0.36) ALOX5APFEN1MAP4K1ADORA3ADORA2B
SCHEMBL2879015 0.77 ALOX5AP (0.37) ALOX5APFEN1NPY5RHPGDSCNR1
SCHEMBL2881781 0.77 ALOX5AP (0.37) ALOX5APFEN1NPY5RHPGDSCNR1
SCHEMBL2881895 0.76 GRIA2 (0.41) ALOX5APFEN1BRAF
SCHEMBL2886881 0.76 GRIA2 (0.41) ALOX5APFEN1BRAF
SCHEMBL2881889 0.76 GRIA2 (0.41) ALOX5APFEN1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US claimed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US claimed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP claimed
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US disclosed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives NPY1R, NPY2R, NPY5R USP30 3878/4885ALOX5AP 1403/4885FEN1 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.